Kemp Dolliver
Stock Analyst at Brookline Capital
(0.46)
# 4,109
Out of 4,981 analysts
17
Total ratings
30.77%
Success rate
-18.4%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.19 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $6.50 | +176.92% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.19 | +1,361.19% | 1 | Jul 15, 2025 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $8.59 | +97.90% | 1 | Dec 5, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $4.83 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.93 | +285.65% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.11 | +1,606.16% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.04 | +2,919.23% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $52.94 | +88.89% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.44 | +2,240.86% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $3.95 | +532.91% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.74 | +295.57% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $1.12 | +614.29% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.99 | +473.31% | 1 | Feb 2, 2022 |
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.19
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $6.50
Upside: +176.92%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.19
Upside: +1,361.19%
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $8.59
Upside: +97.90%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.83
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.93
Upside: +285.65%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.11
Upside: +1,606.16%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.04
Upside: +2,919.23%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $52.94
Upside: +88.89%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.44
Upside: +2,240.86%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.95
Upside: +532.91%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $4.74
Upside: +295.57%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $1.12
Upside: +614.29%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.99
Upside: +473.31%